Similarly, in high-grade ovarian cancer altered BRCA1/2 results in a higher mutational load, therefore, tumors harbor more tumor-specific neoantigens, increased TILs including CD3+ and CD8+ and PD-1 and PD-L1 expression [29,136]. The gene discussed is BRCA1; the disease is ovarian carcinoma.